HTB South

Antiretrovirals

No impact on bioavailability of D/C/F/TAF when tablet is split but TAF absorption is reduced if crushed

Dolutegravir outperforms lopinavir/ritonavir second-line: interim results from the DAWNING study

Reduced-dose darunavir is safe and effective in switch study

Dolutegravir pharmacokinetics in pregnancy

High rates of undocumented efavirenz-related side effects in Uganda

Increased risk of ART failure after low-level viraemia in a large South African cohort

Option B+ Malawi

Pre-ART drug resistance in rural South Africa but limited clinical impact with good adherence

Increased risk of IRIS with integrase inhibitors reported in two studies

Dolutegravir exposure increases when fixed dose combination tablets are crushed

Dose reduction potential of nanoparticle ARV formulations confirmed in humans

Adverse pregnancy outcomes and risk factors in the PROMISE trial

Pharmacokinetics, safety and efficacy of dolutegravir in very young children

Raltegravir pharmacokinetic targets met in high-risk HIV-exposed infants

Tenofovir alafenamide exposure modestly higher in children than adults

VRC01 in HIV-exposed newborns: first results support monthly injections for those at risk through breastfeeding

Dolutegravir use in pregnancy: results from small Belgian cohort

16th European AIDS Conference (EACS 2017)

Dolutegravir-based dual therapy as switch option in multiple studies

Dolutegravir is superior to boosted atazanavir in women in the ARIA study

Dual therapy with dolutegravir + 3TC keep viral load undetectable: 48 week results from PADDLE study

Once-daily raltegravir at last available: 48 week results from ONCEMRK study

Dual long-acting cabotegravir plus rilpivirine injections: 48-week results from LATTE-2

High death rates among HIV positive women postpartum accessing ARVs

Higher rates of eye complications in HIV positive people on ART

Raltegravir-based third-line ART in children and adolescents

Raltegravir in HIV-exposed neonates

Tenofovir-containing ART reduces bone mineral density in breast feeding women: results from IMPAACT P1084s

Pipeline ART: tenofovir alafenamide (TAF)

Pipeline ART: maturation inhibitors and an attachment inhibitor

PrEP reduced HIV risk by at least 86% in PROUD: no transmissions likely from people taking meds

Antiretroviral studies at ICAAC 2014: darunavir-based FDC with TAF, cobicistat, doravirine, Stribild and gel formulation PrEP

Switch from efavirenz to rilpivirine quells CNS toxicity, improves sleep

HIV persists in lung macrophages of people on suppressive ART

Risk of CVD or type-2 diabetes according to change in BMI after starting ART

Pill A, Pill B: simplified second-line treatment for low-income countries

Update on paediatric antiretrovirals

Is d4T a viable option for children in low-income countries?

Short-term safety of atazanavir/ritonavir-based second line treatment in Zambia

Uptake of ART is influenced by distance to the health facility in rural Zambia

ARV pipeline: doravirine, GSK-744 and BMS-068

Viral load rebound rate of 35% using ritonavir-boosted PI monotherapy: results of five-year PIVOT study

Dual therapy less effective at high viral load: NEAT 001 study with raltegravir/darunavir/r

Atazanavir, raltegravir and darunavir virologically equivalent in naive patients but significant differences for tolerability: results from ACTG 5257

Pharmacokinetic targets for efavirenz might be too high

Women, HIV research and antiretrovirals

Outcomes in infants exposed to lopinavir/ritonavir in utero

Two percent rate of efavirenz discontinuation in an ART programme in Malawi

Raltegravir safe and effective in pregnancy in small French study

Side effects common but mostly mild in women taking higher dose protease inhibitors in pregnancy

Good safety profile with long-acting integrase inhibitor GSK744

TAF comparable to TDF in once-daily pill for ART-naive: 48-week results

Dolutegravir superior to darunavir at 48 weeks in open-label ART-naive trial

High prices for antiretrovirals in middle-income countries outside Africa

Comparable efficacy and pregnancy outcomes with boosted atazanavir and lopinavir at standard doses

PrEP gives little extra benefit in attempted conception if male partner is on ART

Cobicistat approved as pharmacokinetic (PK) booster for atazanavir and darunavir in EU prior to the US

NHS England approves four-in-one Stribild (Quad) for limited use

Dolutegravir approved in the US

ViiV goes for gold: US premium pricing may make dolutegravir redundant in the UK

From sky high to CHAI* – what needs to be done about dolutegravir pricing?

Pharmacokinetics of etravirine with once-daily and twice-daily dosing

Efavirenz at 400 mg compared to standard 600 mg dose has similar efficacy with fewer side effects

Dolutegravir update: treatment-naive and -experienced patients and drug resistance

Elvitegravir/cobicisat/tenofovir/FTC: Stribild studies at IAS 2013

Post navigation